According to the reports in the past decades, tyrosine kinase inhibitors(TKIs) targeted to epidermal growth factor receptor(EGFR) may significantly reduce mortality rate of patients with NSCLC [4–5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.